Neutrophil/Lymphocyte Ratio (NLR) as a Predictive Marker for p16 Positivity and Cervical Cancer Progression: Insights from the SCOPE Study

Abstract

Cervical cancer is a major global health concern, primarily caused by persistent high-risk human papillomavirus (HPV) infections. Identifying reliable biomarkers for early disease detection and progression monitoring is crucial. This study examines the relationship between systemic inflammatory markers—neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), and lymphocyte/monocyte ratio (LMR)—and p16 positivity, a key biomarker for HPV-related cervical disease. Our analysis of 395 patients undergoing LEEP conization found that elevated NLR levels were significantly associated with both p16 and HPV DNA positivity, suggesting a link between systemic inflammation and disease progression. These findings highlight the potential of NLR as an accessible and cost-effective prognostic marker, offering valuable insights for improving cervical cancer screening and management. By integrating hematological and immunohistochemical markers, clinicians may enhance risk stratification and personalized patient care.